Oncorus Inc. (ONCR) Appoints Douglas Fambrough to its Board

June 23, 2022 7:04 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Oncorus, Inc. (Nasdaq: ONCR) today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors.

“We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms,” said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. “As a recognized industry leader with extensive experience in RNA medicines and growing successful biotechnology companies, Doug’s appointment highlights Oncorus’ commitment to bringing together innovators of our industry as we progress our pipeline and build upon our platforms. We look forward to working with Doug as we advance our portfolio of differentiated viral immunotherapies to help meaningfully improve the lives of cancer patients.”

“Oncorus’ novel technology is generating a pipeline of uniquely engineered viruses and first-in-class vRNA product candidates. I’m excited to partner with this exceptional team to progress their portfolio of viral immunotherapies and unlock the potential of this modality to activate multiple arms of the immune system, realizing the promise of this new class of medicines in oncology,” said Dr. Fambrough. “I look forward to working with my fellow board members and Oncorus’ leadership team to advance this potentially paradigm-shifting approach to cancer treatment.”

Dr. Fambrough brings over 25 years of clinical and managerial experience to Oncorus. Most recently, he served as co-founder, President and Chief Executive Officer of Dicerna Pharmaceuticals, a publicly traded biotechnology company focused on RNAi-based therapeutics for various disease areas, including oncology. At Dicerna, he was responsible for overseeing the company’s scientific and business success for nearly 12 years leading up to its acquisition by Novo Nordisk in December 2021 for $3.3 billion. Prior to Dicerna, Dr. Fambrough was a general partner at Oxford Bioscience Partners, where he has specialized in financing innovative life science technology companies. While at Oxford, Dr. Fambrough led the investment in the first-generation RNA interference company Sirna Therapeutics and other pioneering biotechnology companies, including Solexa, Xencor, Rib-X Pharmaceuticals, and Solstice Neurosciences. Prior to joining Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genomic Research, now known as the Broad Institute. He holds an A.B. in biology from Cornell University and a Ph.D. in genetics from the University of California, Berkeley.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Board Changes, Corporate News

Related Entities

Definitive Agreement